SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging in conversation as a self-described Bitcoin parody that leans into its origins as an early 2011 internet joke to differentiate itself from newer meme coins. The community is actively debating its potential as a 'next-gen' asset, highlighting its long-standing lore and historical ties to the broader crypto ecosystem while dismissing recent unrelated copycats as scams.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is capturing market attention as the bank navigates a complex environment of shifting private credit regulations and internal loan markdowns, while analysts closely monitor its role in major upcoming IPOs and the broader impact of AI-driven cyber threats on the financial sector. The community is actively debating the bank's defensive positioning and potential earnings strength, with traders specifically focused on its institutional options activity and price action relative to key sector support levels.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is currently a focal point for investors as they anticipate a transformative FDA Biologics License Application (BLA) decision for their lead drug candidate, ivonescimab, which is being positioned as a potential disruptor in the lung cancer treatment landscape. The community is intensely focused on the company's clinical pipeline, with active discussions centering on the upcoming interim progression-free survival data and the broader competitive threat the drug poses to existing blockbuster immunotherapies.

Citigroup Global Markets Holdings, Inc. provides investment banking and securities brokerage services. It offers financial advisory, research and capital raising services to corporations, governments and individuals. The company was founded in 1977 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is currently drawing significant attention from investors as it hits fresh 52-week highs, driven by a combination of successful strategic divestitures in markets like Russia and Mexico and growing market optimism surrounding its long-term profitability overhaul. Traders are actively debating the sustainability of this recent rally, closely monitoring upcoming earnings as a potential catalyst while reacting to regulatory developments that are viewed as a positive signal for the bank's operational flexibility.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is currently generating significant market conversation following a Canary Capital ETF filing that has renewed institutional interest and fueled community speculation about a potential major upward move. Investors are actively debating the token's long-term meme status versus its utility as a blue-chip asset, with many focusing on its price action as a key indicator of broader altcoin market health and potential rotation from Bitcoin.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is trending as investors weigh its role as a lead underwriter for the massive anticipated SpaceX IPO and monitor the bank's active positioning in hedging private credit risk through new credit default swap indices. Additionally, market sentiment is being driven by the firm's robust performance metrics heading into the earnings cycle and its strategic expansion into AI-related infrastructure financing.

Stubhub Holdings, Inc. provides online ticket selling services. It also provides services for buyers and sellers of tickets for sports, concerts, theater, and other live entertainment events. The company was founded by Eric H. Baker in 2000 and is headquartered in New York, NY.

Stubhub Holdings Inc. - Ordinary Shares - Class A

StubHub

StubHub is experiencing significant market volatility and heavy short interest as investors react to its post-IPO performance and lack of near-term guidance. The community remains deeply divided, with some betting on a potential short squeeze fueled by low float, while others express strong skepticism regarding the company's valuation, regulatory headwinds, and the sustainability of its business model in a cooling consumer economy.

Hormel Foods Corp. engages in the manufacturing and marketing of branded food products. It operates through the following segments: Retail, Foodservice, and International. The Retail segment consists of the processing, marketing, and sale of food products sold predominantly in the retail market. The Foodservice segment includes the processing, marketing, and sale of food and nutritional products for foodservice, convenience store, and commercial customers. The International segment focuses on processing, marketing, and selling company products internationally. The company was founded by George A. Hormel in 1891 and is headquartered in Austin, MN.

Hormel Foods Corp.

Hormel Foods is trending after a JPMorgan downgrade to neutral triggered a sell-off, with the community focused on cost pressures and the stock's persistent downtrend. While some investors remain attracted to the company's dividend yield and its role as a defensive staple, others express frustration over its underperformance and management's struggle to navigate inflationary headwinds.

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.

Aktis Oncology Inc

Akoustis Technologies Inc

Akoustis Technologies has completed the sale of its assets to a subsidiary of SpaceX, formally concluding its Chapter 11 bankruptcy process. The community is actively discussing the impact of this liquidation, with many shareholders expressing that their equity positions have been wiped out following the finalization of the sale.

Sweetgreen, Inc. owns and operates a chain of salad restaurants. It offers drinks, sides, local bowls, salads, plates, and warm bowls. The company was founded by Nicolas Jammet, Jonathan Neman, and Nathaniel E. Ru in November 2006 and is headquartered in Los Angeles, CA.

Sweetgreen Inc - Ordinary Shares - Class A

Sweetgreen is trending as market participants focus on significant insider accumulation, including a notable purchase by the CEO, fueling speculation about a potential short squeeze on the heavily shorted stock. Investors are closely monitoring the company's turnaround efforts, specifically the expansion of the 'Infinite Kitchen' technology and new menu additions like wraps, as they look for signs of a recovery in same-store sales and traffic stabilization.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Aberdeen Group plc

Aberdeen Group plc trimmed its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 67.1% during the fourth quarter, according to the company in its most recent Form 13F...

Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price Expected to Rise, Bank of America Analyst Says

Bank of America raised their price objective on shares of Ionis Pharmaceuticals from $100.00 to $111.00 and gave the company a "buy" rating in a research report on Thursday...

Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC lifted its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 548.7% in the 4th quarter, according to the company in its most recent Form 13F filing with...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Rating of "Moderate Buy" by Analysts

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) has received an average rating of "Moderate Buy" from the twenty analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendatio...

Ionis Pharmaceuticals (NASDAQ:IONS) EVP Shannon Devers Sells 6,193 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Shannon Devers sold 6,193 shares of the firm's stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $74.05, for a total transaction of $458,591.65. Following the sale, the executive vice president...

J. Safra Sarasin Holding AG Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS

J. Safra Sarasin Holding AG acquired a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 17,404 shares of the company's stock...

Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza

BIIB gains after the FDA clears higher-dose Spinraza, with data showing improved motor function and potential to counter rising SMA competition.

Assenagon Asset Management S.A. Cuts Stake in Ionis Pharmaceuticals, Inc. $IONS

Assenagon Asset Management S.A. cut its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 90.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,316 shar...

Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market

Ionis Pharmaceuticals cuts Tryngolza price ahead of sHTG decision, with analysts seeing stronger sales potential and competitive positioning.read more...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

IONS
Ionis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IONS News

IONSIonis Pharmaceuticals Inc